Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 4/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 10/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12359084 | 0.87 | CHRNA1 (0.36) | ROCK2KDM1AMAOBLPAR2NPY5R | |
| SCHEMBL12653222 | 0.86 | ROCK2 (0.37) | ROCK2KDM1AMAOBLPAR2TRPV1 | |
| SCHEMBL1800337 | 0.85 | CHUK (0.40) | ROCK2KDM1ALPAR2TRPV1NPY5R | |
| SCHEMBL1797750 | 0.83 | TRPV1 (0.52) | ROCK2TRPV1NPY5R | |
| SCHEMBL1798709 | 0.83 | TRPV1 (0.52) | ROCK2TRPV1NPY5R | |
| SCHEMBL1797596 | 0.83 | TRPV1 (0.52) | ROCK2TRPV1NPY5R | |
| SCHEMBL1799978 | 0.83 | PARP1 (0.43) | ROCK2LPAR2TRPV1KCNH2PARP1 | |
| SCHEMBL1800621 | 0.83 | TRPV1 (0.52) | ROCK2TRPV1NPY5R | |
| SCHEMBL1797782 | 0.83 | POLB (0.45) | ROCK2TRPV1NPY5R | |
| SCHEMBL1796493 | 0.83 | TRPV1 (0.52) | ROCK2TRPV1NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190344-A1 | BENZIMIDAZOLE MODULATORS OF VR1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190344-A1 | BENZIMIDAZOLE MODULATORS OF VR1 | VRK1, VRK2, VIL1 | ROCK2 4179/4885KDM1A 1102/4885MAOB 2944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.